ARA-290 (Cibinetide) Research Guide Ireland

Overview

ARA-290, also known by its INN Cibinetide, is an 11-amino acid synthetic peptide developed by Araim Pharmaceuticals as a non-hematopoietic derivative of erythropoietin (EPO). It was engineered to retain EPO's tissue-protective signalling while removing the erythropoietic (red blood cell-stimulating) activity that limits EPO's use outside of anaemia treatment. ARA-290 is designed to selectively activate the innate repair receptor (IRR), a heterodimer of the EPO receptor and the CD131 beta common receptor subunit, rather than the classical homodimeric EPO receptor responsible for erythropoiesis. Research into ARA-290 has focused primarily on small nerve fibre function, neuropathic pain, and inflammatory/metabolic signalling. It has been studied in randomised, placebo-controlled human trials in type 2 diabetes patients with painful neuropathy and in patients with sarcoidosis-associated small nerve fibre loss. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

ARA-290 is designed as a selective agonist of the innate repair receptor (IRR), a receptor complex proposed to form from the heterodimerisation of the erythropoietin receptor (EPOR) and the CD131 beta common receptor subunit shared with GM-CSF, IL-3 and IL-5 receptors. This is distinct from the classical (EPOR)2 homodimer responsible for erythropoiesis in bone marrow progenitor cells. Because ARA-290 does not efficiently activate the homodimeric EPOR, research models report it does not stimulate red blood cell production in the way native EPO does. Activation of the IRR by ARA-290 is investigated for downstream effects including modulation of nuclear factor-kappa B (NF-κB) signalling, reduction of pro-inflammatory cytokine release, and support of endothelial and neuronal cell survival pathways. Preclinical models have examined ARA-290's role in protecting small nerve fibres and supporting tissue repair processes following ischaemic, metabolic, or inflammatory injury, without the thrombotic and cardiovascular risk signals associated with erythropoiesis-stimulating agents.

Research Areas & Reported Effects

Diabetic Neuropathic Pain

The most developed area of ARA-290 research is painful diabetic neuropathy. A Phase 2 randomised, double-blind, placebo-controlled trial in patients with type 2 diabetes and confirmed small nerve fibre neuropathy examined self-administered subcutaneous ARA-290 over several weeks. Researchers assessed changes in neuropathic pain symptom scores, corneal nerve fibre density (via corneal confocal microscopy), and quantitative sensory testing.

Sarcoidosis-Associated Small Fibre Neuropathy

ARA-290 has been studied in patients with sarcoidosis who present with small nerve fibre loss and associated symptoms such as fatigue and neuropathic pain, independent of active granulomatous disease. Placebo-controlled trials in this population assessed the Small Fiber Neuropathy Screening List (SFNSL) score and other patient-reported symptom measures alongside corneal nerve fibre density.

Inflammatory and Metabolic Signalling

Preclinical and early mechanistic studies have investigated ARA-290's influence on markers of systemic inflammation and metabolic parameters, including its interaction with innate immune signalling pathways implicated in chronic low-grade inflammation associated with metabolic disease.

Tissue and Nerve Repair Models

Animal studies have explored ARA-290's tissue-protective properties in models of nerve injury and ischaemia-reperfusion injury, examining whether IRR activation supports neuronal survival and functional recovery without the erythropoietic side effects associated with EPO analogues.

Research Data Summary

Study / Model	Reported Effect
Phase 2 RCT — Painful Diabetic Neuropathy (Brines M et al.)	Reported reductions in neuropathic pain symptom scores and improvements in corneal nerve fibre density measures versus placebo over the study period.
Phase 2 RCT — Sarcoidosis-Associated Small Fibre Neuropathy	Reported improvements in Small Fiber Neuropathy Screening List scores relative to placebo in a subset of treated patients.
Preclinical models (rodent nerve injury)	Reported support of neuronal survival and reduced inflammatory markers following IRR activation, without erythropoietic response.
In vitro endothelial/neuronal cell models	Reported modulation of NF-κB-related inflammatory signalling and cell survival pathway activity following ARA-290 exposure.

Stack Combinations Studied

• ARA-290 alone (monotherapy design) → Research rationale: Nearly all published human trials to date have studied ARA-290 as a standalone investigational agent rather than in combination with other peptides, to isolate its effect on IRR-mediated pain and nerve fibre outcomes.
• ARA-290 + standard-of-care glycaemic management → Research rationale: In diabetic neuropathy trials, ARA-290 was studied as an add-on to participants' existing glucose-lowering treatment, not as a replacement, to assess incremental effect on neuropathic symptoms.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Published Phase 2 Trial Protocol	Approximately 1-4 mg (fixed dose per published trial design)	4-8 weeks	Alternate days (subcutaneous, self-administered in trial)	Painful diabetic neuropathy and sarcoidosis-associated small fibre neuropathy trials.
Preclinical Rodent Model Protocol	Species- and study-specific (µg/kg range reported in literature)	Days to several weeks	Daily to alternate-day dosing in reported models	Nerve injury, ischaemia-reperfusion and inflammatory signalling models.

Observed Side Effects in Research

• Injection site reactions (redness, mild discomfort)
• Headache
• Mild gastrointestinal symptoms reported in some trial participants
• No clinically significant increase in haemoglobin or haematocrit reported, consistent with its non-erythropoietic design

Published trials report ARA-290 as generally well tolerated, with no serious treatment-related adverse events consistently identified across the completed Phase 2 studies. The research base remains limited to a small number of trials and cohorts, so the long-term safety profile has not been established.

Compound Data

CAS Number

1206676-05-7

Molecular Formula

C₅₂H₇₆N₁₆O₁₆ (approximate, 11-residue linear peptide)

Molecular Weight

Approximately 1257 g/mol

Half-Life

Short plasma half-life (minutes range); biological effect proposed to outlast plasma clearance via receptor-mediated signalling

Synonyms

Cibinetide, ARA 290, Innate Repair Receptor agonist peptide

Research Classification

Non-hematopoietic erythropoietin-derived peptide, Innate Repair Receptor (IRR) agonist

Scientific References

• [Brines M et al. 2008] — Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. — Journal of Internal Medicine — [Review / Mechanistic]
• [Brines M et al. 2014] — ARA 290, a non-erythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. — Molecular Medicine — [Human RCT]
• [Culver DA et al. 2017] — Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. — Investigative Ophthalmology & Visual Science — [Human RCT]
• [Dahan A et al. 2013] — ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss. — Journal of Pain Research — [Human RCT]
• [Brines M, Cerami A 2012] — The receptor that tames the innate immune response. — Molecular Medicine — [Review / Mechanistic]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*